C
Charlotte Roach
Researcher at Agilent Technologies
Publications - 14
Citations - 5985
Charlotte Roach is an academic researcher from Agilent Technologies. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 9, co-authored 12 publications receiving 4861 citations. Previous affiliations of Charlotte Roach include Merck & Co. & Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Journal ArticleDOI
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil Daud,Jedd D. Wolchok,Caroline Robert,Wen-Jen Hwu,Jeffrey S. Weber,Antoni Ribas,F. Stephen Hodi,Anthony M. Joshua,Richard F. Kefford,Richard F. Kefford,Richard F. Kefford,Peter Hersey,Richard W. Joseph,Tara C. Gangadhar,Roxana S. Dronca,Amita Patnaik,Hassane M. Zarour,Charlotte Roach,Grant Toland,Jared Lunceford,Xiaoyun Nicole Li,Kenneth Emancipator,Marisa Dolled-Filhart,S. Peter Kang,Scot Ebbinghaus,Omid Hamid +25 more
TL;DR: PD-L 1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.
Journal ArticleDOI
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
Charlotte Roach,Nancy Zhang,Ellie Corigliano,Malinka Jansson,Grant Toland,Gary Ponto,Marisa Dolled-Filhart,Kenneth Emancipator,Dave Stanforth,Karina Kulangara +9 more
TL;DR: PD-L1 IHC 22C3 pharmDx is a sensitive, precise, and robust companion diagnostic assay, which will facilitate safe and effective use for pembrolizumab in cancer patients.
Journal ArticleDOI
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Rina Hui,Edward B. Garon,Jonathan W. Goldman,Natasha B. Leighl,Matthew D. Hellmann,Amita Patnaik,Leena Gandhi,Joseph Paul Eder,Myung-Ju Ahn,Leora Horn,Enriqueta Felip,Enric Carcereny,Reshma A. Rangwala,Gregory M. Lubiniecki,Jin Zhang,Kenneth Emancipator,Charlotte Roach,Naiyer A. Rizvi +17 more
TL;DR: Pembrolizumab provides promising long-term OS benefit with a manageable safety profile for PD-L1-expressing treatment-naive advanced NSCLC, with greatest efficacy observed in patients with TPS ≥50%.
Journal ArticleDOI
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Marisa Dolled-Filhart,Charlotte Roach,Grant Toland,Dave Stanforth,Malinka Jansson,Gregory M. Lubiniecki,Gary Ponto,Kenneth Emancipator +7 more
TL;DR: The PD-L1 immunohistochemical assay shows the potential for enrichment of trial populations and as a companion diagnostic tool in non-small cell lung cancer.